Current status of CPT and its analogues in the treatment of malignancies
- 367 Downloads
Camptothecin (CPT) is a kind of terpene indole alkaloid which was firstly isolated from native Chinese happy tree Camptotheca acuminata and owns a unique anti-tumor mechanism by inhibiting Topo I. Being approved by FDA, the camptothecin derivatives, irinotecan and topotecan, are extensively used for the treatment of various cancers throughout the world. In the past decades, pharmacology of CPT and its analogues has been well documented. This review will focus on different human malignancies with demonstrated clinical efficacy of CPT analogues.
KeywordsAnalogues Camptothecin Chemotherapy Malignancies
The authors are grateful for financial sponsored by the Shanghai Committee of Science and Technology, China (13140902402).
Conflict of interest
The authors confirm that this article content has no conflicts of interest.
- Brave M, Dagher R, Farrell A et al (2006) Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer. Oncology (Williston Park) 20:1401–1404Google Scholar
- Fujii T, Kunikane H, Okamoto H et al (2009) A phase II study of cisplatin and irinotecan as induction chemotherapy followed by accelerated hyperfractionated thoracic radiotherapy with daily low-dose carboplatin in unresectable stage III non-small cell lung cancer: JCOG 9510. Jpn J Clin Oncol 39:784–790PubMedGoogle Scholar
- Jemal A, Center MM, DeSantis C et al (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomark Prev 19:1893–1907Google Scholar
- Papadimitriou CA, Papakostas P, Karina M et al (2011) A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study. BMC Med 9:10PubMedCentralPubMedGoogle Scholar
- Sehouli J, Stengel D, Harter P et al (2011) Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 29:242–248PubMedGoogle Scholar
- Takeda K, Negoro S, Tanaka M et al (2011) A phase II study of cisplatin and irinotecan as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706. Jpn J Clin Oncol 41:25–31PubMedGoogle Scholar
- von Pawel J, Schiller JH, Shepherd FA et al (1999) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17:658–667Google Scholar